BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.5M data for 737K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for G Deshmukh

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
GluN2A-Selective Pyridopyrimidinone Series of NMDAR Positive Allosteric Modulators with an ImprovedEBI
Genentech
Discovery of GluN2A-Selective NMDA Receptor Positive Allosteric Modulators (PAMs): Tuning Deactivation Kinetics via Structure-Based Design.EBI
Pharmaron-Beijing
Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12).EBI
Wuxi Apptec
Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models.EBI
Genentech
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.EBI
Genentech
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1.EBI
Argenta Discovery
Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.EBI
Genentech
Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR).EBI
Genentech
Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.EBI
Genentech
Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.EBI
Genentech
Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.EBI
Genentech
Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.EBI
Genentech
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.EBI
Argenta Discovery
Potency-Enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability.EBI
Genentech
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.EBI
Relay Therapeutics
Discovery of a Novel Potent and Selective Calcium Release-Activated Calcium Channel Inhibitor: 2,6-Difluoro-EBI
Lupin
Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group.EBI
Genentech
Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.EBI
Genentech
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.EBI
Genentech
Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.EBI
Wuxi Apptec
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.EBI
Genentech